CORPORATE Update

Indian Renewable Energy Development Agency (IREDA)

Q2 YoY: Loan sanctions jump 86% to ₹33,148 Cr vs ₹17,860 Cr.

Loan disbursements up 54% to ₹15,043 Cr vs ₹9,787 Cr.

Pfizer

Secures a three-year reprieve from US tariffs on pharmaceutical imports imposed by former President Trump.

Pharmaceutical Sector

Trump’s 100% tariff will take effect from Oct 1, 2025.

Tata Motors

Incorporates TML CV Holdings BV in the Netherlands.

Invests ₹120 Cr via Series C Compulsorily Convertible Preference Shares.

Acquires 49,500 equity shares (~₹14 Cr) in Freight Commerce Solutions; expects 42–46% stake on fully diluted basis.

IndusInd Bank

Appoints Anand Vardhan as General Counsel and Senior Management Personnel; previously Group General Counsel at Piramal Group.

Man Industries

SEBI penalties imposed for non-consolidation of financials with Merino Shelters (FY2015–21).

Individuals barred from securities market for two years.

Company states core operations unaffected; strong order book (~₹4,700 Cr).

Nestle India

Signs MoU with Ministry of Food Processing Industries at World Food India Summit.

Plans to expedite greenfield (Odisha) and brownfield projects over next 2–3 years.

HUDCO

Sanctions ₹92,710 Cr and disburses ₹25,839 Cr in loans for H1 FY26.

Q2 disbursements grow 43.6% YoY to ₹13,026 Cr.

United Spirits

Clarifies it will not comment on reports regarding stake sale of Royal Challengers Bengaluru.

DLF

Approves allotment of 1.1 lakh NCDs worth ₹1,100 Cr via private placement.

Infibeam Avenues

Transfers investments in IPMPL to subsidiary Rediff.com India Ltd as part of slump sale of platform business undertaking.

Jaiprakash Associates

CCCI approval received for acquisition by Jindal Power, part of Jindal Group.

Shree Cement

Commissions 3.65 MTPA clinkerisation unit at Jaitaran integrated plant, Rajasthan.

Atlantaa

Signs ₹2,485 Cr EPC contract with IRCON International for Bhandara–Gadchiroli Access Controlled Expressway (Maharashtra).

Lupin

Receives US FDA approval for Rivaroxaban Oral Suspension (bioequivalent to Xarelto, Janssen).

Indicated for pediatric VTE and thromboprophylaxis.